We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
An approach to payment for providers of IAPT services that links payment to patient outcomes as well as the provider’s levels of activity.
Summarises progress made and outlines further critical steps required to ensure that the right drugs are available
Read about talking therapies and counselling for mental health problems.
How to use a multiphase optimisation strategy (MOST) to evaluate your digital health product.
Patients with recurring lymphoma, or who have not responded to prior treatments, could access a new bispecific antibody therapy to help treat their condition.
For the first time, patients with certain types of advanced or recurrent endometrial cancer could access a treatment shown to slow its progression
Legislation title: Guidance on the application of Plant Protection Products (PPPs) for phytosanitary treatment of oak processionary moth (OPM).
Projects granted during 2016 that have a primary purpose of translational and applied research - human cancer.
Explains testing from 1 April 2024 onwards and sets out the purpose of ongoing testing, who will be eligible to access testing and when tests should be used.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
The epidemiology, symptoms, diagnosis and management of human T-cell lymphotropic virus types 1 and 2 (HTLV-1 and HTLV-2).
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).